Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

Commenting on the launch, Sanjeev Krishan, President, Glenmark North America said, "We are very pleased to bring to market a lower cost alternative to Gilenya® Capsules, 0.5 mg. This launch confirms our commitment to provide quality and affordable pharmaceutical products to patients."

According to IQVIATM sales data for the 12-month period ending September 2022, the Gilenya® Capsules, 0.5 mg market achieved annual sales of approximately $1.8 billion*.

Glenmark's current portfolio consists of 176 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 404.40 as compared to the previous close of Rs. 399.75. The total number of shares traded during the day was 48237 in over 2273 trades.

The stock hit an intraday high of Rs. 409.30 and intraday low of 398.75. The net turnover during the day was Rs. 19546520.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 FingolimodCapsules